准确的分期通过增加提供适合分期的治疗的机会来提高肺癌的生存率。然而，用于肺癌分期的指南推荐的诊断测试的利用不足且存在差异。因此，美国癌症协会全国肺癌圆桌会议 (ACS NLCRT) 召集了适当治疗分类任务组（一个多学科专家和利益相关者小组），以确定导致指南分期不一致的知识和/或资源差距，并提出克服这些问题的建议差距。任务组确定了以下内容： 差距 1：指南一致分期的促进因素和障碍尚未完全了解；建议 1：确定与指南一致的肺癌分期的促进因素和障碍；差距 2：支持分期算法的证据水平为低至中等；建议2：优先考虑评估肺癌分期的比较有效性研究；差距 3：不同专业协会的指南建议各不相同；建议 3：协调各专业协会的指南建议；差距 4：现有数据库不包含足够的信息来衡量与指南一致的分期；建议 4：用衡量指南一致分期所需的信息扩充现有数据库；差距5：卫生系统没有肺癌分期的绩效反馈机制；建议5：制定并实施肺癌分期绩效反馈机制；差距6：患者很少自我主张采用与指南一致的分期；建议 6：增加患者自我倡导符合指南分期的机会；差距 7：当前的卫生政策并未促使肺癌分期符合指南；建议 7：在 ACS NLCRT 下组织一个代表性工作组，推动制定符合指南的肺癌分期政策。通俗易懂的总结：分期（确定癌症扩散的程度）很重要，因为它可以帮助临床医生选择最佳的癌症治疗方法。接受最好的癌症治疗会给患者带来最好的治疗结果。实践指南旨在帮助临床医生对肺癌患者进行分期。然而，美国的肺癌分期通常与实践指南的建议有所不同。本报告确定了改善肺癌分期的七个机会。© 2024 作者。 《癌症》由 Wiley periodicals LLC 代表美国癌症协会出版。

Accurate staging improves lung cancer survival by increasing the chances of delivering stage-appropriate therapy. However, there is underutilization of, and variability in, the use of guideline-recommended diagnostic tests used to stage lung cancer. Consequently, the American Cancer Society National Lung Cancer Roundtable (ACS NLCRT) convened the Triage for Appropriate Treatment Task Group-a multidisciplinary expert and stakeholder panel-to identify knowledge and/or resource gaps contributing to guideline-discordant staging and make recommendations to overcome these gaps. The task group determined the following: Gap 1: facilitators of and barriers to guideline-concordant staging are incompletely understood; Recommendation 1: identify facilitators of and barriers to guideline-concordant lung cancer staging; Gap 2: the level of evidence supporting staging algorithms is low-to-moderate; Recommendation 2: prioritize comparative-effectiveness studies evaluating lung cancer staging; Gap 3: guideline recommendations vary across professional societies; Recommendation 3: harmonize guideline recommendations across professional societies; Gap 4: existing databases do not contain sufficient information to measure guideline-concordant staging; Recommendation 4: augment existing databases with the information required to measure guideline-concordant staging; Gap 5: health systems do not have a performance feedback mechanism for lung cancer staging; Recommendation 5: develop and implement a performance feedback mechanism for lung cancer staging; Gap 6: patients rarely self-advocate for guideline-concordant staging; Recommendation 6: increase opportunities for patient self-advocacy for guideline-concordant staging; and Gap 7: current health policies do not motivate guideline-concordant lung cancer staging; Recommendation 7: organize a representative working group under the ACS NLCRT that promotes policies that motivate guideline-concordant lung cancer staging. PLAIN LANGUAGE SUMMARY: Staging-determining the degree of cancer spread-is important because it helps clinicians choose the best cancer treatment. Receiving the best cancer treatment leads to the best possible patient outcomes. Practice guidelines are intended to help clinicians stage patients with lung cancer. However, lung cancer staging in the United States often varies from practice guideline recommendations. This report identifies seven opportunities to improve lung cancer staging.© 2024 The Author(s). Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.